Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report

BACKGROUND: Tyrosine kinase inhibitors (TKI) have been the standard first-line therapy for advanced non-small cell lung cancer (NSCLC) of epidermal growth factor receptor (EGFR) sensitive mutations. Uncommon EGFR mutations are increasingly reported with the development of next-generation sequencing....

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Fei, Xia, Meng-Ling, Pan, Hui-Yun, Pan, Jiong-Wei, Shen, Yi-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258371/
https://www.ncbi.nlm.nih.gov/pubmed/35979118
http://dx.doi.org/10.12998/wjcc.v10.i17.5916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258371/
https://www.ncbi.nlm.nih.gov/pubmed/35979118
http://dx.doi.org/10.12998/wjcc.v10.i17.5916

Ejemplares similares